Asthma advice

Article source Link, Article source Link,

Prenatal care is 35th in the world, resulting in truly astounding numbers of deaths at childbirth and life long diseases and disabilities. Preventative care is falling by the wayside, because we can't afford it. And drug companies spend more money promoting three competing penis hardening drugs than they do on scientific research and development of new drugs.
After all, limp penises are far more important than cancer cures, HIV vaccines, asthma treatment, stem cell cures for paralysis and other major life changed problems.
Limp penises. Yeah, that is the perfect description of today's corporate America

Excluding special items, net income declined to $12.02 million or $0.10 per share, from $39.71 million, or $0.34 per share, in the prior-year third quarter. The special items include an income tax benefit as a result of the release of a valuation allowance on deferred tax assets, an after-tax in-process research and development charge and certain other items. On average, 15 analysts polled by First Call/Thomson Financial expected earnings of $0.14 a share.
Quarterly total revenues increased to $307.67 million from $280.76 million in the year-ago quarter. Analysts' estimated revenue of $292.29 million.
Brand-wise, Lunesta, for the treatment of insomnia, generated revenues of $154.7 million compared to $160.7 million last year. Xopenex, a short-acting beta-agonist indicated for the treatment or prevention of bronchospasm in patients with asthma and chronic obstructive pulmonary disease accounted $77.9 million of revenues for the third quarter compared to $91.6 million for the third quarter 2007. Xopenex HFA metered-dose inhaler formulation of levalbuterol, accounted for $18.5 million of revenues during the third quarter 2008 compared to $17.1 million last year. And, BROVANA brand generated $14.8 million in the third quarter compared to $2.4 million for the same period in 2007.
Revenues from net product sales increased to $289.25 million from $271.84 million, while revenues from royalties and license fees more than doubled to $18.42 million from $8.92 million.
Research and development expenses for the quarter rose to $63.01 million from $49.03 million last year. Total operating expenses for the quarter rose to $268.69 million from $224.15 million prior year. 1 2 Next Page

Blog Archives:
Moped and scooters

Refinish kitchen cabinets

Abercrombie polo shirt

Sealing tile grout

Installing ceramic tiles

Vintage cowboy shirt

Kitchen cabinet hinge

White kitchen cabinet

Chinese moped

Razz moped

Asthma articles

Piaggio mopeds

Toddler polo shirt

Company logo shirts

Cabinet catches

Yamaha mopeds

Dragon shirts

Scooters and mopeds

Moped helmets

Asthma attack relief